Head and Neck Cancer Trial, Recruiting NCT06744296 Sponsor: Massachusetts Eye and Ear Infirmary Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT06744296
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with Stage III to Stage IVB squamous cell cancer (a type of cancer) in the mouth, nose, sinuses, throat, voice box, or related areas of the head and neck, based on the AJCC 8th edition staging system.
  • People who have tumor tissue available that can be used to create a personalised cancer DNA tracking test (called a tumor-informed ctDNA panel).
  • People whose planned standard treatment — either surgery or a combination of chemotherapy and radiation — is scheduled to take place at Massachusetts Eye and Ear Institute (MEEI) or within the Massachusetts General Hospital (MGH) Cancer Center, including the Boston, Danvers, and Newton-Wellesley locations.

Who may not be able to join:

  • People under 18 years of age.
  • People whose treatment plan falls outside of standard medical care, as decided by the clinical investigator.
  • People who have already had surgery (other than a small incisional biopsy), radiation, or chemotherapy for this type of head and neck cancer before enrolling in the trial.
  • People who are currently taking part in another clinical trial involving an experimental treatment at the time of joining.
  • People whose cancer has spread to distant parts of the body such as the lungs, bones, or liver (classified as AJCC Stage IVC), confirmed by biopsy.
  • People who currently have another active cancer that is not the head and neck cancer being studied.
  • People who are pregnant during the treatment period.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Daniel Faden, MD, Massachusetts Eye and Ear

Phone: 617-573-6060

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Massachusetts Eye and Ear Infirmary
Registry
ClinicalTrials.gov
Start date
3 February 2025
Est. completion
6 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

2 Years - Disease Free Survival (DFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov